Chelidonine enhances the antitumor effect of lenvatinib on hepatocellular carcinoma cells

BACKGROUND: Lenvatinib is a newly approved molecular targeted drug for the treatment of advanced hepatocellular carcinoma (HCC). However, the high cost associated with this treatment poses a huge financial burden on patients and the entire public health system. Therefore, there is an urgent need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Fang-jie, Guo, Li-xiao, Zheng, Kai-yan, Song, Jun-na, Wang, Qian, Zheng, Yu-guang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707434/
https://www.ncbi.nlm.nih.gov/pubmed/31695406
http://dx.doi.org/10.2147/OTT.S215103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6707434/
https://www.ncbi.nlm.nih.gov/pubmed/31695406
http://dx.doi.org/10.2147/OTT.S215103

Ejemplares similares